Q.  What does NeoStem do? 

A. NeoStem, Inc. ("we," "NeoStem" or the "Company") continues to develop and build on its core capabilities in cell therapy to capitalize on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. Our January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") provides NeoStem with a foundation in both manufacturing and regulatory affairs expertise. We believe this expertise, coupled with our existing research capabilities and collaborations, will allow us to achieve our mission of becoming a premier cell therapy company. Our PCT subsidiary's manufacturing base is one of the few current Good Manufacturing Practices ("cGMP") facilities available for contracting in the burgeoning cell therapy industry. Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and is enrolling a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. We also expect to begin a Phase 1 clinical trial by 2013 to investigate AMR-001's utility in arresting the progression of congestive heart failure and the associated comorbidities of that disease. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is engaged in collaboration with Becton-Dickinson that is exploring the earlier stage clinical development of a T-cell therapy for autoimmune conditions. In addition, our pre-clinical assets include our VSELTM Technology platform as well as our MSC (mesenchymal stem cells) product candidate for regenerative medicine.

Q. What is NeoStem’s relationship with Progenitor Cell Therapy, LLC?

A. NeoStem is a 100% owner of Progentor Cell Therapy, LLC (PCT), and its subsidiary, NeoStem Family Storage, a private cord blood banking business. NeoStem completed the acquisition of PCT on January 19, 2011 and has retained the management team of PCT.

Q. What is NeoStem’s relationship with Amorcyte?

A. Amorcyte is a wholly owned subsidiary of NeoStem.

Q. What is NeoStem’s relationship with Athelos Inc.?

A. Athelos is a Delaware corporation 80% owned by NeoStem through its wholly owned subsidiary, PCT. To further expand and diversify NeoStem’s efforts in cell therapy, the mission of Athelos is to develop regulatory T cells (T-reg) as a therapeutic to treat disorders of the immune system. Through exclusive world-wide licenses, Athelos has secured the rights to a broad patent estate within the T-reg field.

Q.  How can I download the Amorcyte AMR-001 Video?

A. Click here to download the Amorcyte AMR-001 Video in Flash.

Q.  What is NeoStem’s Financial Conflict of Interest Policy?

A.  Please visit the Company's Financial Conflict of Interest Policy by clicking here.

Q.  What is NeoStem’s ticker symbol, exchange and CUSIP

A.  The Company’s common stock is traded under the ticker symbol NBS on NYSE MKT. The CUSIP for the common stock is 640650305.

Q.  How many common shares does NeoStem have outstanding?

A.  129.9 million shares of the Company's common stock were outstanding as of March 31, 2012.

Q.  What is NeoStem’s fiscal year?

A.  The Company’s fiscal year ends on December 31.

Q.  Who is NeoStem’s IR contact?

A.   
Trout Group
Gitanjali Jain Ogawa, Vice President
Phone: (646) 378-2949
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

NeoStem, Inc.
Robin Smith, CEO
Phone: (212) 584-4174
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Q.  Who are NeoStem's auditor and corporate legal counsel?

Q.  Who is NeoStem’s transfer agent?

A. Our transfer agent is Continental Stock Transfer & Trust Company (www.continentalstock.com)